US 11,814,446 B2
Immunotherapy against several tumors including lung cancer
Toni Weinschenk, Aichwald (DE); Steffen Walter, Reutlingen (DE); Jens Fritsche, Dusslingen (DE); Colette Song, Ostfildern (DE); and Harpreet Singh, Munich (DE)
Assigned to IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed by IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE)
Filed on Apr. 23, 2021, as Appl. No. 17/238,932.
Application 17/238,932 is a continuation of application No. 16/599,198, filed on Oct. 11, 2019, granted, now 11,161,877.
Application 16/599,198 is a continuation of application No. 16/444,693, filed on Jun. 18, 2019, granted, now 10,479,818, issued on Nov. 19, 2019.
Application 16/444,693 is a continuation of application No. 15/639,165, filed on Jun. 30, 2017, abandoned.
Application 15/639,165 is a continuation of application No. 14/908,078, abandoned, previously published as PCT/EP2014/066755, filed on Aug. 4, 2014.
Claims priority of provisional application 61/862,213, filed on Aug. 5, 2013.
Claims priority of application No. 1313987 (GB), filed on Aug. 5, 2013; and application No. 1403297 (GB), filed on Feb. 25, 2014.
Prior Publication US 2021/0253640 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/06 (2006.01); C07K 7/08 (2006.01); C12N 5/0783 (2010.01); C12N 9/64 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 38/1709 (2013.01); A61K 39/0011 (2013.01); A61K 45/06 (2013.01); C07K 7/06 (2013.01); C07K 14/7051 (2013.01); C12N 5/0638 (2013.01); C12N 9/6491 (2013.01); C12Y 304/24065 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C12N 2502/11 (2013.01)] 20 Claims
 
1. A peptide consisting of the amino acid sequence SLYKGLLSV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt.